NOL3 is a predictor of patient outcome

摘要

The present invention features a method for determining the prognosis for survival of a cancer patient. Methods for measuring the level of NOL3 expression in a cancer cell-containing sample from a patient, and comparing the level of NOL3 expression in the sample to a reference level of NOL3 expression are also included. A higher level of NOL3 relative to the reference level correlates with decreased survival of the patient, and an equivalent or lower level of NOL3 relative to the reference level correlates with increased survival of the patient.

主权项

1. A method of selecting a subject having cancer for a treatment regimen and treating said subject having cancer comprising:
(a) measuring the level of NOL3 expression in a cancer cell-containing sample from said subject having cancer; (b) measuring a reference level of NOL3 expression in a sample from a subject without the cancer; (c) comparing the level of NOL3 expression in said cancer cell-containing sample to the reference level of NOL3 expression; (d) selecting said subject having cancer for a treatment regimen when the level of NOL3 expression in the cancer cell-containing sample is greater than the reference level of NOL3 expression; and (e) administering a therapeutically effective amount of imatinib to said subject having cancer selected in step (d).